eylea sbla dose approv
medicar shift could impos price
fda approv sbla eylea dose help build competit
expect fda approv sbla dose eylea wet
provid eylea market share protect brolucizumab threat
novarti port deliveri system pd format lucenti genentech
wet space remind investor pd system still earli stage
develop safeti data yet releas determin clinic applic
furthermor believ nv tri fit brolucizumab dose schedul
rather maxim efficaci wet may good approach sinc
hawk studi harrier studi subject dose
indic signific number patient still requir frequent dose
maintain view still face meaning headwind growth given
increas eylea discount us eylea sale make major
revenu time come
concern eylea fail medicar part negoti scheme potenti
concern provid medicar advantag plan option
negoti part drug price particularli plan also offer part sinc
plan would abl cross-manag across part could potenti
place eylea part within part negoti scheme creat addit price
pressur medicar advantag plan allow take advantag price
negoti option start expect appli newli prescrib
medic monitor price negoti scheme roll-out close
maintain hold rate price target expect multipl near-
term posit catalyst like dupix approv uncontrol persist asthma
cemiplimab approv cscc octob view sbla approv posit
could help mitig potenti competit novarti genentech
extent howev hold view need focu develop asset
would provid full econom compani
biotech discov
invent manufactur commerci medicin
treat seriou diseas
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
aug oct oct ph studi osteoarthritisfda decis bla advanc csccdata ph polypsregulatori ex-u regulatori agenc decis applic adult atop dermat regulatori investig new drug applic ind antibodyfda regulatori submiss npdr non-dm patientsregulatori sbla expand indic adolesc year age atop dermatitisfda decis uncontrol persist asthmadata ph one-year data panorama trial npdr innon-dm patientsfda decis sbla use apheresi figur valuat dcf
regeneron dcf valuat free yoy depreci less capit less work capit free firm yoy discount rate pv termin net outstand valu per equityrisk-fre growth ratewacctermin growth ratetvdiscount rate regeneron
fy producteyleau ex-u arcalystu ex-u revenues- net product sale book praluentu ex-u ww zaltrap- ww kevzara- us revenu probabl adjust ex-u revenu probabl adjust dupixent- us atop uncontrol asthma- ex-u atop uncontrol asthma- figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sanofi bayer option non-reimburs sell gener option sg collabor total oper profit loss oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss interest expens convert debtnon-cash interest relat convert senior notesadjust net net incom loss ep fulli ep fulli share dilut share outstand dilut share outstand
